Cmed Technology Invited to Participate at World TB Day
Cmed Technology, an eClinical technology provider, announced today it has been invited to participate at the annual World TB Day, which is being held tomorrow at Washington, D.C.’s U.S. Capitol Visitor Center. Throughout the day, Cmed Technology will conduct live demonstrations of its latest on-demand eClinical platform, Timaeus 5, using an Apple iPad®.
Tomorrow’s Senate briefing discusses the current state of tuberculosis (TB) and drug-resistant TB strains. Tuberculosis is a global problem; one of 10 people infected will develop the active form of the disease during their lifetime, according to the World Health Organization (WHO). The Bacille Calmette Guerin (BCG) vaccine, which is currently the only available vaccine against tuberculosis, provides limited protection against pulmonary tuberculosis and is not effective in adults. There is currently no licensed vaccine in the United States.
Cmed Technology’s Timaeus, which manages clinical data from Study Design through Reporting, has been supporting large-scale TB trials in difficult and remote geographies since 2008. In many countries, especially developing countries, trial sites may be situated in remote locations where Internet connectivity is unstable or not available at all. Because Timaeus allows clinicians to maintain full data communication using only mobile and/or low-speed connections without loss of performance, clinical trial sites can electronically capture data on-demand, allowing the data to be managed and reviewed in real time regardless of a site’s location.
“Cmed Technology Group feels honored to have been asked to participate at World TB Day because of our Timaeus eClinical platform being used to capture, manage and report clinical trial data in remote geographies with challenging circumstances,” said James Haughwout, Cmed Technology’s Vice President of Commercialization and Operations. “By giving trial sites the means to not being tethered to fixed, high-speed Internet connections, Cmed Technology is letting physicians bring innovation to wherever patients are located. Our hope is that Timaeus will help speed up the development of TB vaccines and treatments.”
What: World TB Day, demonstration of Timaeus 5 using an Apple iPad®
Where: U.S. Capitol Visitor Center, Rooms 210-212, Washington, D.C.
When
: March 24, 2011 (Thursday), 11 a.m.-2 p.m.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
